USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Takeda Pharmaceutical Company Limited

USPTO PatentsView assignee record - 668 granted patents across 61 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Takeda ranks #675 of 49,997 tracked US assignees by granted-patent volume, with 668 patents across 61 technology areas.

#675
of 49,997 US assignees by volume
Top 2%
by Innovation Score (64.7/100)
13.9
avg claims per patent
+4%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R675 · Foreign Corporation #675 · 668 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MID 668 grants
  • TOP-DECILE #675/49,997
  • PHOTO-FINISH Socionext
  • CPC-WIDE A61P · 61 areas
  • INNOV-STRONG 64.7/100
  • CLAIMS-RICH 13.9 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-FLAT +4% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Socionext Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Takeda

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Takeda's Innovation Score is 64.7/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Takeda's grant cadence moved

Between 2020–2024, Takeda Pharmaceutical Company Limited received 305 grants versus 294 in 2015–2019 (+4% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2024 at 77 grants and bottomed in 2020 at 46. Lead class A61P accounts for 80.1% of the portfolio across 61 subclasses. Volume neighbours: BAE Systems PLC (#671) and Datang Mobile Communications Equipment Co., Ltd. (#679).

Takeda's three-year grant acceleration

From 2019–2021 to 2022–2024, Takeda Pharmaceutical Company Limited moved from 155 to 207 grants (1.33x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #599. See the growth leaderboard.

Who files at Takeda's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Takeda holds 668 patents at rank #675, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Takeda

By rank, the assignees closest to #675 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Takeda's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Takeda, neither rank-band nor same-CPC leaders (those blocks stay above).

Takeda's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

65 Top 2% higher than 98% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

4050607080 20152016201720182019202020212022202320242025 69
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Takeda Pharmaceutical Company Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 67 10.0%
2016 62 9.3%
2017 61 9.1%
2018 47 7.0%
2019 57 8.5%
2020 46 6.9%
2021 52 7.8%
2022 60 9.0%
2023 70 10.5%
2024 77 11.5%
2025partial year 69 10.3%

Which technologies does Takeda Pharmaceutical Company Limited patent most?

Top 15 of 61 technology areas

Where it ranks

Overall rank by patents

#675

of 49,997 tracked assignees

Innovation Score

64.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Takeda Pharmaceutical Company Limited's patent record in context - here's where to go next.

  • Takeda Pharmaceutical Company Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.1% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #675 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Takeda Pharmaceutical Company Limited against BAE Systems PLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 64.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.